Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

Detalles Bibliográficos
Autores principales: Evans, D. Gareth, Howell, Sacha J., Howell, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784814/
https://www.ncbi.nlm.nih.gov/pubmed/31444676
http://dx.doi.org/10.1007/s10689-019-00142-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784814/
https://www.ncbi.nlm.nih.gov/pubmed/31444676
http://dx.doi.org/10.1007/s10689-019-00142-8

Ejemplares similares